APA (7th ed.) Citation

Thomas Bieber, Norito Katoh, Eric L. Simpson, Marjolein de Bruin-Weller, Diamant Thaçi, Antonio Torrelo, . . . Jacob P. Thyssen. (2023). Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: An updated integrated analysis of eight clinical trials. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Thomas Bieber, et al. Safety of Baricitinib for the Treatment of Atopic Dermatitis over a Median of 1.6 Years and Up to 3.9 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials. Taylor & Francis Group, 2023.

MLA (9th ed.) Citation

Thomas Bieber, et al. Safety of Baricitinib for the Treatment of Atopic Dermatitis over a Median of 1.6 Years and Up to 3.9 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials. Taylor & Francis Group, 2023.